Dr. Muro Discusses Safety Data from Asian XELIRI Project in CRC

Kei Muro, MD
Published: Thursday, Feb 02, 2017



Kei Muro, MD, Aichi Cancer Center Hospital, discusses the findings of Asian XELIRI project (AXEPT) in colorectal cancer (CRC).

This multinational, randomized, phase III trial of the combination of capecitabine and irinotecan (XELIRI) evaluated safety with or without bevacizumab (Avastin) versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic CRC.

Results showed that bevacizumab did not change safety profiles in either the XELIRI or FOLFIRI arms. Both were both well tolerated, says Muro, with incidence of toxicities slightly lower in the XELIRI arm at 53.2% compared with 73% in the FOLFIRI arm.
 


Kei Muro, MD, Aichi Cancer Center Hospital, discusses the findings of Asian XELIRI project (AXEPT) in colorectal cancer (CRC).

This multinational, randomized, phase III trial of the combination of capecitabine and irinotecan (XELIRI) evaluated safety with or without bevacizumab (Avastin) versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic CRC.

Results showed that bevacizumab did not change safety profiles in either the XELIRI or FOLFIRI arms. Both were both well tolerated, says Muro, with incidence of toxicities slightly lower in the XELIRI arm at 53.2% compared with 73% in the FOLFIRI arm.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x